Form 8-K - Current report:
SEC Accession No. 0001493152-24-040953
Filing Date
2024-10-11
Accepted
2024-10-11 17:05:23
Documents
17
Period of Report
2024-10-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 51894
2 ex5-1.htm EX-5.1 11629
3 form8-k_001.jpg GRAPHIC 5309
4 ex10-1.htm EX-10.1 267215
  Complete submission text file 0001493152-24-040953.txt   625198

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cldi-20241011.xsd EX-101.SCH 3813
6 XBRL DEFINITION FILE cldi-20241011_def.xml EX-101.DEF 30090
7 XBRL LABEL FILE cldi-20241011_lab.xml EX-101.LAB 36817
8 XBRL PRESENTATION FILE cldi-20241011_pre.xml EX-101.PRE 27113
19 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6006
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 241368168
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)